乳腺癌TOP2A基因表达与含蒽环类药物新辅助化疗效果的关系  

Relationship between expression of TOP2A in breast cancer and anthracycline-based neoadjuvant chemotherapy

作　　者：蒋奕[1] 叶新青[2] 廖晓明[1] 姬逸男[1] 唐玮[1] 叶洪涛 

机构地区：[1]广西医科大学附属肿瘤医院乳腺外科,广西南宁530021 [2]广西医科大学附属肿瘤医院病理科,广西南宁530021 [3]英国国立皇家骨科医院病理科

出　　处：《中国医药导报》2016年第35期16-19,F0003,共5页China Medical Herald

基　　金：广西壮族自治区科学研究与技术开发计划项目(桂科攻14124004-1-12);广西壮族自治区自然科学基金青年基金资助项目(2012GXNSFBA053115);广西壮族自治区卫生厅自筹科研经费课题(Z2011224)

摘　　要：目的探讨乳腺癌拓扑异构酶ⅡA（TOP2A）基因表达与含蒽环类药物新辅助化疗疗效的关系。方法收集广西医科大学附属肿瘤医院乳腺外科2010年2月～2014年3月收治的91例乳腺癌患者新辅助化疗粗针穿刺的病理标本，采用荧光原位杂交（FISH）法检测癌组织中TOP2A与HER2基因表达，采用免疫组织化学法（IHC）检测ER、HER2和TOPOⅡα蛋白的表达，并观察应用含蒽环类药物新辅助化疗后病理情况。结果TOP2A基因表达与HER2基因及TOPOⅡα蛋白表达相关（P〈0．05），而与ER、HER2蛋白表达无关（P〉0．05）。经新辅助化疗后TOP2A基因扩增的患者获得的pCR率（50．0％）优于未扩增者（5．5％）（P〈0．05）。结论乳腺癌TOP2A基因表达与HER2基因及TOPOⅡα蛋白相关，而与ER、HER2蛋白表达量无关。TOP2A基因扩增程度可能为评估含蒽环类药物新辅助化疗疗效的预测因子。Objective To evaluate the relationship between the expression of TOP2A and efficacy of anthracycline- based neoadjuvant chemotherapy in breast cancer. Methods 91 patients with breast cancer who were treated in Depart- ment of Breast Surgery, Tumor Hospital Affiliated to Guangxi Medical University from February 2010 to March 2014 were surveied; a core needle biopsy was used to collect samples before and after neoadjuvant chemotherapy, fluores- cence in situ hybridization （FISH） was performed to assess expression of TOP2A and HER2 gene, an immunohistochem- istry （1HC） was then employed to check the changes of protein expression levels of ER, HER2 and TOPO Ⅱα. The pathological was observed after neoadjuvant chemotherapy with anthracyclines. Results TOP2A gene expression had relevant with HER2 gene and TOPO Ⅱ alpha protein expression （P 〈 0.05）, and had nothing to do with ER, HER2 protein expression （P 〉 0.05）. Patients with TOP2A gene amplification had a high rate of pCR （50.0%） than in patients with failure TOP2A gene amplification （5.5%）. Conclusion TOP2A gene expression in breast cancer has relevant with HER2 gene and TOPO Ⅱ alpha protein expression, and has nothing to do with ER and HER2 protein status. TOP2A gene amplification can be the predictive factor for anthracycline-based chemotherapy.

关 键 词：乳腺癌 新辅助化疗 拓扑异构酶ⅡA HER2 

分 类 号：R737.9[医药卫生—肿瘤]